# Heather Roxborough

> Heather Roxborough is a Series A investor at Oxford Science Enterprises backing Health Care. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-sciences-innovation)
- Location: London, United Kingdom
- Total investments: 9
- Last investment: Jan 2025
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: http://uk.linkedin.com/pub/heather-roxborough/3/35b/589

Heather Roxborough is a Series A investor at Oxford Science Enterprises in London focused on Health Care and Biotechnology. Heather Roxborough - Partner @ Optum Ventures

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 44% |
| Biotechnology | 3 | 33% |
| Medical | 2 | 22% |
| Hospital | 2 | 22% |
| Therapeutics | 2 | 22% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 56% |
| Seed | 1 | 11% |
| Series B | 1 | 11% |
| Series C | 1 | 11% |
| Venture - Series Unknown | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 44% |
| Belgium | 1 | 11% |
| United States | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neu Health | Neu Health enables clinicians, caregivers, and patients to tackle this growing challenge with cutting-edge digital technologies. | $2M | Seed | Jan 29, 2025 |  |
| Amber Therapeutics | Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system. | $101.8M | Series A | Jun 09, 2024 |  |
| Navenio | Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons orwi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.The company was founded in 2015 and is headquartered in Oxford, England. | $6.3M | Series A | Sep 20, 2023 |  |
| Caristo Diagnostics | Caristo Diagnostics is revolutionizing cardiovascular diagnostics and risk prediction with its advanced, AI-based CT imaging analysis tools. | $16.3M | Series A | Apr 17, 2023 |  |
| Navenio | Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons orwi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.The company was founded in 2015 and is headquartered in Oxford, England. | $12.6M | Venture - Series Unknown | Dec 14, 2021 |  |
| Kaia Health | Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of disorders including back pain and COPD. Working with experts in various medical fields, the company uses machine learning to deliver individualized app interventions that aim to empower and motivate patients to take control and self-manage theircondition with digital alternatives from their home using devices they already own (i.e. smartphones and tablets).The company has enrolled more than 400,000 users to date in its digital therapy program. It was founded in 2016 and is headquartered in Brooklyn, New York. | $75M | Series C | Apr 28, 2021 |  |
| Kaia Health | Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of disorders including back pain and COPD. Working with experts in various medical fields, the company uses machine learning to deliver individualized app interventions that aim to empower and motivate patients to take control and self-manage theircondition with digital alternatives from their home using devices they already own (i.e. smartphones and tablets).The company has enrolled more than 400,000 users to date in its digital therapy program. It was founded in 2016 and is headquartered in Brooklyn, New York. | $26M | Series B | Jun 18, 2020 |  |
| icometrix | icometrix provides clinicians with standardized measurements on their patients’ brain MRI scans in order to improve personalized care of people with a neurological disorder.icometrix was founded in 2011 by Dirk Loeckx and Wim Van Hecke. It is a spin-off company of the universities and university hospitals of Leuven and Antwerp. Today, icometrixhas grown to a team of over 25 people and is internationally active, with headquarters in Leuven and an office in Boston, USA. They are the worldwide standard in MRI biomarkers in routine clinical practice.icometrix developed MSmetrix, which detects brain lesions, calculates lesion volume and measures the whole brain and grey matter volume and atrophy. MSmetrix, received market approval in the EU and other countries including Canada, Brazil and Australia. FDA clearance is pending. Furthermore, icometrix is ISO9001 and ISO13485 (Medical Devices) and ISO27001 (Information Security) certified.icometrix also acts as an image analysis expert in clinical trials and research studies. Imaging biomarkers constantly lead to new insights on neurological disorders. Since recently, imaging biomarker outcomes often serve as the primary endpoints in clinical trials for the development of new drugs. For these purposes large batches of brain imaging data are frequently transferred to icometrix for fast and high quality processing. This way our software-as-a-service is incorporated in clinical trials and large research studies regarding Traumatic Brain Injury (TBI), Epilepsy, Alzheimer’s Disease, Stroke, etc. | $18M | Series A | May 14, 2019 |  |
| Kaia Health | Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of disorders including back pain and COPD. Working with experts in various medical fields, the company uses machine learning to deliver individualized app interventions that aim to empower and motivate patients to take control and self-manage theircondition with digital alternatives from their home using devices they already own (i.e. smartphones and tablets).The company has enrolled more than 400,000 users to date in its digital therapy program. It was founded in 2016 and is headquartered in Brooklyn, New York. | $8M | Series A |  |  |

9 of 9 investments shown.

## Co-investors
- [3VC](https://shizune.co/investors/profile/3vc) — VC Fund, 4 deals together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-science-enterprises) — VC Fund, 4 deals together
- [Balderton Capital](https://shizune.co/investors/profile/balderton-capital) — VC Fund, 2 deals together
- [BGF Ventures](https://shizune.co/investors/profile/bgf-ventures) — VC Fund, 2 deals together
- [Big Pi Ventures](https://shizune.co/investors/profile/big-pi-ventures) — VC Fund, 2 deals together
- [Cedars Sinai](https://shizune.co/investors/profile/cedars-sinai-medical-centerr) — VC Fund, 2 deals together

## About Oxford Science Enterprises

VC Fund · Oxford, United Kingdom

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

5 contacts available at Oxford Science Enterprises.

| Name | Title | Profile |
| --- | --- | --- |
| Alexis Dormandy | Chief Executive Officer | https://shizune.co/investors/profile/alexis-dormandy |
| Alexis Zervoglos | Senior Partner (Technology) | https://shizune.co/investors/profile/alexis-zervoglos |
| Claire Brown | Partner ( Life Sciences) | https://shizune.co/investors/profile/claire-brown |
| Ekaterina Smirnyagina | Senior Partner and Head of Life Sciences | https://shizune.co/investors/profile/ekaterina-smirnyagina |
| David Norwood | Chairman | https://shizune.co/investors/profile/david-norwood |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Heather Roxborough invest in?

Heather Roxborough invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Heather Roxborough last invest?

The most recent investment recorded for Heather Roxborough closed in Jan 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co